Lipid Emulsion Dosing for Local Anesthetic Systemic Toxicity (LAST)
For LAST in both adults and children, administer 20% lipid emulsion (Intralipid®) as an initial bolus of 1.5 mL/kg over 2-3 minutes, followed immediately by a continuous infusion of 0.25 mL/kg/min (15 mL/kg/hr). 1
Initial Bolus and Infusion Protocol
The 2025 AHA Guidelines provide the most current evidence-based dosing:
- Initial bolus: 1.5 mL/kg of 20% lipid emulsion given over 2-3 minutes
- Continuous infusion: 0.25 mL/kg/min (equivalent to 15 mL/kg/hr)
- Repeat bolus: If cardiovascular instability persists after 5 minutes, give another 1.5 mL/kg bolus and increase infusion to 0.5 mL/kg/min
- Maximum cumulative dose: Approximately 10-12 mL/kg over the first 30 minutes 1
This dosing applies equally to adults and children, as pediatric recommendations are extrapolated from adult data and case series showing successful outcomes 1, 2.
Critical Implementation Points
Start lipid emulsion immediately when LAST is suspected—do not wait for confirmatory testing or laboratory results. The 2023 AHA Focused Update emphasizes that ILE is particularly efficacious for bupivacaine-induced toxicity but should be used for all local anesthetic toxicities 3.
Timing Matters for Outcomes
Evidence shows that approximately 55% of pediatric patients who received ILE within 10 minutes of LAST onset had better cardiovascular outcomes 2. Early administration in conjunction with prevention of hypoxia and acidemia through standard advanced life support has been associated with successful resuscitation in animal studies, case reports (including pregnant women and children), and registry studies 1.
Concurrent Management Requirements
While administering lipid emulsion:
- Maintain airway and oxygenation: Hypoxia and acidemia increase local anesthetic toxicity, particularly with bupivacaine 1
- Treat seizures aggressively: Give benzodiazepines immediately for seizure activity, as seizures worsen hypoxia/acidemia and increase cardiotoxicity risk 1
- Consider sodium bicarbonate: May overcome sodium channel blockade, particularly for cardiovascular manifestations 1
- Avoid propofol: Do NOT attempt to replicate lipid dosing with propofol—this would require 10-20 times the induction dose and cause serious CNS/cardiovascular adverse effects 1
Important Caveats
Use only 20% lipid emulsion formulations. The majority of animal studies and human experience specifically use 20% ILE 1. The FDA-approved Intralipid® dosing for nutritional purposes differs significantly from LAST treatment protocols 4—do not confuse these indications.
Administration Technical Details
- Use a 1.2-micron filter (filters <1.2 microns must not be used) 4
- Can infuse through the same line as other resuscitation medications via Y-connector
- Consider non-DEHP administration sets, as lipid emulsions extract DEHP from PVC components 4
When to Escalate
If the patient remains in cardiac arrest or refractory shock despite lipid emulsion therapy, prepare for venoarterial extracorporeal membrane oxygenation (VA-ECMO) early—implementation takes time, so initiate the process before complete cardiovascular collapse 3.
Post-Resuscitation Monitoring
Observe patients for at least 24 hours after stabilization, as biphasic toxicity can occur 5. Continue monitoring even if initial symptoms resolve quickly, particularly in older patients or those with cardiovascular comorbidities.
The evidence supporting this dosing regimen comes from three RCTs (n=40) demonstrating pharmacokinetic benefits, extensive animal models, case reports with successful outcomes in adults and children, and registry data 1. While publication bias exists (few reports of ILE failure), the overwhelming evidence supports its use as a cornerstone therapy for LAST with minimal reported adverse effects when used at recommended doses 1, 2, 6.